Chris Meekins, FBR research analyst, discusses three reasons to ignore Donald Trump's comments against the current drug prices.
CNBC's Meg Tirrell reports on which names in biotech were hit hardest last year by Hillary Clinton's tweet calling price gouging "outrageous."
The drug is for the treatment of moderate to severe menapause symptoms like hot flashes and night sweats.
CNBC's Martin Soong reports on the growth potential of the pharmaceutical industry in India, the largest generic drug producer in the world.
Shares of TherapeuticsMD jump on positive drug trial results, CNBC's Seema Mody reports. Paul Hickey, Bespoke Investment Group, and CNBC's Mike Santoli weigh in.
David Schenkein, Agios CEO, speaks to CNBC's Meg Tirrell about his company's pyruvate kinase deficiency drug, stock performance and innovation.
CNBC's Meg Tirrell discusses big movers in biotech, including Kite Pharmaceuticals and Bluebird Bio.
Shares of Eli Lilly gains momentum on news of an FDA drug approval. CNBC's Seema Mody reports.
Kara Swisher, Recode executive editor, shares her take on the Theranos board, calling it "the most unusual board in Silicon Valley."
Jim Cramer says investors need to be careful in high-risk cancer immunotherapy stocks.
CNBC's Meg Tirrell speaks to Brent Saunders, Allergan CEO, about the drug industry's new era under a Trump presidency.
CNBC's Meg Tirrell speaks to Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, about Trump's effect on biotech, drug pricing and the study against high cholesterol.
CNBC's Meg Tirrell speaks to Robert Nelsen, ARCH Venture Partners founder, about Trump's potential impact on the drug industry, and the future of biotech.
Sources say the Valeant-Takeda deal is "all but dead." CNBC's Scott Wapner reports the details, as well as how the market is reacting to this news.
Christopher Weaver, Wall Street Journal reporter, discusses Theranos' "smart money" investors, as well as the company's recent challenges.
Jason Kolbert, Maxim Group, and Les Funtleyder, ESquared, discuss biotech opportunities in Cuba post-Castro.
Thernos is being sued for alleged fraud by Robert Colman, Robertson Stephens co-founder. CNBC's Sue Herera reports.
Alex Tarrant, assistant editor at Dealreporter Europe, weighs in on Johnson & Johnson's proposed acquisition of Swiss biotechnology company Actelion.
Robyn Karnauskas, Citi Research lead biotech analyst, weighs in on the drop in Juno Therapeutics following the company's study halt.
The “Fast Money Halftime Report” traders weigh in on the biotech sector, with Eli Lilly and Juno Therapeutics stocks dropping significantly.